Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia (ESCAPE1b)

NCT01426334 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01426334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01426334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia (ESCAPE1b)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2011
Completion date
Not reported
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myelogenous leukemia, chronic myelogenous leukemia, bcr-abl1 positive, chronic phase chronic myelogenous leukemia, relapsing chronic myelogenous leukemia